LOS ANGELES, Feb. 6, 2018 /PRNewswire/ -- CytRx
Corporation (NASDAQ: CYTR), a biopharmaceutical research and
development company specializing in oncology, today announced that
Chairman and CEO Steven A. Kriegsman and David Haen,
Vice President of Business Development and Investor Relations, will
present at the 2018 BIO CEO & Investor
Conference on Monday, February 12th at 10:15
a.m. Eastern Time at the New York Marriott Marquis
Hotel.
A live and archived webcast of the presentation will be
available at
http://www.veracast.com/webcasts/bio/ceoinvestor2018/12110299856.cfm.
As previously announced, CytRx plans to present at the
following future investor conference:
30th Annual ROTH Conference
March 11-13, 2018 (exact date
and time TBD)
The Ritz Carlton, Laguna Niguel, CA
Presentation dates and times, along with any links to potential
webcasts for the Roth Conference, will be provided closer to the
actual event.
About the 2018 BIO CEO & Investor Conference
The 2018 BIO CEO & Investor Conference is one of the largest
investor conferences focused on established and emerging publicly
traded and select private biotech companies. The conference, now in
its 20th year, provides a forum where institutional investors,
industry analysts, and senior biotechnology executives have the
opportunity to shape the future investment landscape of the
biotechnology industry.
About CytRx Corporation
CytRx Corporation (NASDAQ: CYTR) is a biopharmaceutical
company specializing in research and clinical development of novel
anti-cancer drug candidates that employ linker technologies to
enhance the accumulation and release of drug at the tumor. CytRx is
also rapidly expanding its pipeline of ultra-high potency oncology
candidates at its laboratory facilities in Freiburg, Germany, through its LADR™ (Linker Activated
Drug Release) technology platform, a discovery engine designed to
leverage CytRx's expertise in albumin biology and linker technology
for the development of a new class of potential breakthrough
anti-cancer therapies. Aldoxorubicin, CytRx's most advanced
drug conjugate, is an improved version of the widely used
anti-cancer drug doxorubicin and has been out-licensed to NantCell,
Inc.
Forward-Looking Statements
This press release contains forward-looking statements. Such
statements involve risks and uncertainties that could cause actual
events or results to differ materially from the events or results
described in the forward-looking statements, including risks and
uncertainties relating to plans for regaining compliance with the
Nasdaq rules and higher share price of our common stock; the
ability of NantCell, Inc., to obtain regulatory approval for its
products that use aldoxorubicin; the ability of NantCell, Inc., to
manufacture and commercialize products or therapies that use
aldoxorubicin; the amount, if any, of future milestone and royalty
payments that we may receive from NantCell, Inc.; our ability to
develop new ultra-high potency drug candidates based on our
LADRTM technology platform; and other risks and
uncertainties described in the most recent annual and quarterly
reports filed by CytRx with the Securities and Exchange Commission
and current reports filed since the date of CytRx's most recent
annual report. All forward-looking statements are based upon
information available to CytRx on the date the statements are first
published. CytRx undertakes no obligation to publicly update or
revise any forward-looking statements, whether as a result of new
information, future events or otherwise.
Investor Relations Contact:
Argot Partners
Michelle Carroll/Sean Augustine-Obi
(212) 600-1902
michelle@argotpartners.com
sean@argotpartners.com
View original
content:http://www.prnewswire.com/news-releases/cytrx-corporation-to-present-at-the-2018-bio-ceo--investor-conference-300594028.html
SOURCE CytRx Corporation